Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder

PURPOSE: Long-term persistence with pharmacotherapy for overactive bladder (OAB) requires a drug with an early onset of action and good efficacy and tolerability profile. Although antimuscarinics improve OAB symptoms within 1–2 weeks of initiating treatment, adherence after 3 months is relatively po...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapple, Christopher R., Nitti, Victor W., Khullar, Vik, Wyndaele, Jean Jacques, Herschorn, Sender, van Kerrebroeck, Philip, Blauwet, Mary Beth, Siddiqui, Emad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236626/
https://www.ncbi.nlm.nih.gov/pubmed/24458878
http://dx.doi.org/10.1007/s00345-014-1244-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236626/
https://www.ncbi.nlm.nih.gov/pubmed/24458878
http://dx.doi.org/10.1007/s00345-014-1244-2

Ejemplares similares